New drug combo shows promise for Tough-to-Treat blood cancer

NCT ID NCT03478514

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day cycles. This is not a cure, but aims to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Medical University of South Carolina - Hollings Cancer Center

    Charleston, South Carolina, 29425, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • St. Joseph Mercy Hospital Cancer Care Center

    Ypsilanti, Michigan, 48197, United States

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, 21201, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27599, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.